Earnings ·
QIAGEN N.V. filed its U.S. GAAP quarterly report for the period ended June 30, 2026
QGENQiagen N.V.
QIAGEN N.V. filed its U.S. GAAP quarterly report for the period ended June 30, 2026. For the six months ended June 30, net sales increased to $1,027.4 million from $1,017.0 million, while net income declined to $171.4 million from $187.0 million. The company declared a cash dividend of $0.35 per share for the quarter ended June 30, 2026, compared to $0.25 per share in the prior year period. Additionally, QIAGEN executed capital repayments totaling $496.9 million during the first half of 2026, reducing its common shares outstanding from 217.7 million to 206.8 million. The company operates in the life sciences industry, providing sample and assay technologies for molecular diagnostics.